Cost-effectiveness of olopatadine was assessed through a literature search and available information. Seasonal allergic conjunctivitis is a nonlife threatening disease associated with increased health expenditures, decrease in quality of life and a large number of days off work and school. Few studies have been performed on the cost-effectiveness of compounds aimed at treating seasonal allergic conjunctivitis. Olopatadine is a new, dual-action compound indicated in the treatment of seasonal allergic conjunctivitis which has been found in clinical trials to be more potent and efficacious than currently available treatments. The rare cost-effectiveness studies performed on olopatadine in seasonal allergic conjunctivitis showed that given its higher efficacy, it could save around euro10 of relapse direct costs in a range of European settings. Further research is required in order to estimate precisely the cost-effectiveness of this compound, particularly including indirect costs and in other countries.